Insmed stock hits 52-week high at 106.84 USD
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Insmed Inc (INSM)
Insmed Inc stock price live, this page displays NASDAQ INSM stock exchange data. View the INSM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Insmed Inc real time stock price chart below.
What Is the Insmed Inc Stock Price Today?
The Insmed Inc stock price today is 107.88.
What Is the Stock Symbol for Insmed Inc?
The stock symbol for Insmed Inc is ""INSM.""
What Stock Exchange Does Insmed Inc Trade On?
Insmed Inc is listed and trades on the NASDAQ stock exchange.
Is Insmed Inc a Good Stock to Buy?
Determining whether Insmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INSM quote. (ISIN: US4576693075)
What Is the Insmed Inc Stock Price Today?
The Insmed Inc stock price today is 107.88.
What Is the Stock Symbol for Insmed Inc?
The stock symbol for Insmed Inc is ""INSM.""
What Stock Exchange Does Insmed Inc Trade On?
Insmed Inc is listed and trades on the NASDAQ stock exchange.
Is Insmed Inc a Good Stock to Buy?
Determining whether Insmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INSM quote. (ISIN: US4576693075)
107.84
+2.66(+2.53%)
Real-time Data·
Fair Value
An estimate of a Insmed's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
105.18
108.42
52 wk Range
60.40
108.42
INSM Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Trading near 52-week High
More Info
Fair Value
An estimate of a Insmed's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
105.18108.42
52 wk Range
60.40108.42
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INSM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Insmed's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
115.71
Upside
+7.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
- Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Insmed stock hits 52-week high at 106.84 USD
- Investing.com
- Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed chair and CEO Lewis sells $699k in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Insmed Inc Company Profile
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Inc SWOT Analysis
Rare Disease Pionee | Insmed's focus on serious and rare diseases positions it as a potential leader in niche markets, with innovative therapies addressing unmet medical needs |
Brenso's Breakthrough | Explore the market potential of Insmed's lead candidate Brenso, poised for FDA approval and commercial launch in bronchiectasis treatment |
Financial Trajectory | Despite current losses, Insmed shows strong revenue growth and improving EPS projections, with analyst price targets ranging from $67 to $110 per share |
Strategic Expansion | Delve into Insmed's pipeline diversification, geographic expansion plans, and potential for partnerships, driving long-term growth beyond current markets |
Insmed Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue beat expectations at $92.82M, but EPS missed at -$1.42 vs -$1.35 forecast
- Strong international growth, with Japan and Europe sales up ~50%; U.S. ARIKAYCE sales increased 14%
- Stock fell 0.82% to $67.72 pre-market despite revenue beat, reflecting EPS miss and spending concerns
- Company maintains $1.2B cash balance, prepares for brensocatib launch with FDA decision expected by August 12
- Insmed forecasts 29% revenue growth for FY2025, continuing 22% CAGR over past five years
Last Updated: 08/05/2025, 14:50
Read Full TranscriptCompare INSM to Peers and Sector
Metrics to compare | INSM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINSMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.2x | −3.8x | −0.5x | |
PEG Ratio | 1.54 | −0.11 | 0.00 | |
Price/Book | 206.6x | 3.5x | 2.6x | |
Price / LTM Sales | 53.8x | 45.4x | 3.3x | |
Upside (Analyst Target) | 4.3% | 160.2% | 42.4% | |
Fair Value Upside | Unlock | 21.2% | 7.2% | Unlock |
Analyst Ratings
18 Buy
0 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 115.71
(+7.29% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-1.42 / -1.35
Revenue / Forecast
92.82M / 90.78M
People Also Watch
FAQ
What Stock Exchange Does Insmed Trade On?
Insmed is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Insmed?
The stock symbol for Insmed is "INSM."
What Is the Insmed Market Cap?
As of today, Insmed market cap is 20.43B.
What Is Insmed's Earnings Per Share (TTM)?
The Insmed EPS (TTM) is -5.89.
When Is the Next Insmed Earnings Date?
Insmed will release its next earnings report on 22 Oct 2025.
From a Technical Analysis Perspective, Is INSM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Insmed Stock Split?
Insmed has split 2 times.
How Many Employees Does Insmed Have?
Insmed has 1271 employees.
What is the current trading status of Insmed (INSM)?
As of 31 Jul 2025, Insmed (INSM) is trading at a price of 107.84, with a previous close of 105.18. The stock has fluctuated within a day range of 105.18 to 108.42, while its 52-week range spans from 60.40 to 108.42.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.